Fernando Laguía Nueda obtained a degree in Biotechnology from the Polytechnic University of Valencia (UPV) in 2015. He completed his studies with an MSc in Experimental Biomedicine from the University of Castilla-La Mancha (UCLM) in 2017 and an MSc in Biomedicine from the University of Barcelona (UB). He completed his Master’s internship in Castration-Resistant Prostate Cancer at the Germans Trias i Pujol Research Institute. For 2 years, he has worked as a researcher in in vitro evaluation of drug combination to treat EGFR and KRAS mutant lung adenocarcinoma in 2D and 3D models. He is currently completing a PhD in the Retrovirology and Clinical Studies group at IrsiCaixa, focused on understanding the endocytic signalling pathway triggered upon virus interaction to Siglec-1 in myeloid cells.